METHODS FOR TREATING HCV
The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV...
Saved in:
Main Authors | , , , , , , , , |
---|---|
Format | Patent |
Language | English French |
Published |
08.10.2015
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.
La présente invention concerne des thérapies sans interféron pour le traitement du VHC. De préférence, la durée du traitement est réduite, par exemple à une durée n'excédant pas 12 semaines. Dans un aspect, le traitement comprend l'administration d'au moins deux agents antiviraux à action directe à un sujet ayant une infection par le VHC, le traitement durant 12 semaines et ne comprenant pas l'administration d'interféron ni de ribavirine, et lesdits au moins deux agents antiviraux à action directe comprenant (a) le composé 1 ou un sel pharmaceutiquement acceptable de ce composé et (b) le composé 2 ou un sel pharmaceutiquement acceptable de ce composé. |
---|---|
AbstractList | The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.
La présente invention concerne des thérapies sans interféron pour le traitement du VHC. De préférence, la durée du traitement est réduite, par exemple à une durée n'excédant pas 12 semaines. Dans un aspect, le traitement comprend l'administration d'au moins deux agents antiviraux à action directe à un sujet ayant une infection par le VHC, le traitement durant 12 semaines et ne comprenant pas l'administration d'interféron ni de ribavirine, et lesdits au moins deux agents antiviraux à action directe comprenant (a) le composé 1 ou un sel pharmaceutiquement acceptable de ce composé et (b) le composé 2 ou un sel pharmaceutiquement acceptable de ce composé. |
Author | LIN, CHIH-WEI DUTTA, SANDEEP AWNI, WALID M PODSADECKI, THOMAS J LIU, WEI WANG, TIANLI BERNSTEIN, BARRY M MENON, RAJEEV M CAMPBELL, ANDREW L |
Author_xml | – fullname: BERNSTEIN, BARRY M – fullname: LIN, CHIH-WEI – fullname: CAMPBELL, ANDREW L – fullname: LIU, WEI – fullname: AWNI, WALID M – fullname: MENON, RAJEEV M – fullname: PODSADECKI, THOMAS J – fullname: WANG, TIANLI – fullname: DUTTA, SANDEEP |
BookMark | eNrjYmDJy89L5WSQ8HUN8fB3CVZw8w9SCAlydQzx9HNX8HAO42FgTUvMKU7lhdLcDApuriHOHrqpBfnxqcUFicmpeakl8c6ORpYmRhZGxo6GxkQoAQB13iDZ |
ContentType | Patent |
DBID | EVB |
DatabaseName | esp@cenet |
DatabaseTitleList | |
Database_xml | – sequence: 1 dbid: EVB name: esp@cenet url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP sourceTypes: Open Access Repository |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Chemistry Sciences |
DocumentTitleAlternate | METHODES DE TRAITEMENT DU VHC |
ExternalDocumentID | CA2942823A1 |
GroupedDBID | EVB |
ID | FETCH-epo_espacenet_CA2942823A13 |
IEDL.DBID | EVB |
IngestDate | Fri Jul 19 14:48:26 EDT 2024 |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | false |
Language | English French |
LinkModel | DirectLink |
MergedId | FETCHMERGED-epo_espacenet_CA2942823A13 |
Notes | Application Number: CA20152942823 |
OpenAccessLink | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20151008&DB=EPODOC&CC=CA&NR=2942823A1 |
ParticipantIDs | epo_espacenet_CA2942823A1 |
PublicationCentury | 2000 |
PublicationDate | 20151008 |
PublicationDateYYYYMMDD | 2015-10-08 |
PublicationDate_xml | – month: 10 year: 2015 text: 20151008 day: 08 |
PublicationDecade | 2010 |
PublicationYear | 2015 |
RelatedCompanies | ABBVIE INC |
RelatedCompanies_xml | – name: ABBVIE INC |
Score | 3.009069 |
Snippet | The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as... |
SourceID | epo |
SourceType | Open Access Repository |
SubjectTerms | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES |
Title | METHODS FOR TREATING HCV |
URI | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20151008&DB=EPODOC&locale=&CC=CA&NR=2942823A1 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LT8MwDLamgWA3GKCNl3pAvVXQ93aoUJe2FKS20yjTblMSEmmXbWKd-Pu4oRtc4BYlkp1YcuzPsR2AO1NSlzPO68g9AhTqvRvUl65hctcTwrOGjl0XOGe5l745LzN31oLFrhZG9Qn9VM0RUaM46nul7uv1TxArUrmVm3u2wKnVY1IGkd6gYzRfaNP0aBTE4yIqiE5IQEI9nwTIFMGFHSJQOkAv2q-zv-LpqC5KWf-2KMkJHI6R2LI6hZZYduGY7D5e68JR1rx347BRvc0Z9LK4TIvoVUPYppWTOCyf8yctJdNz0JK4JKmBLOb748xJuN-MfQFtRPmiBxodDixTovckuONIZlKLW0IwaXqWP3hgtA_9P8lc_rN2BZ1aLt9pa9fQrj624gbtaMVulQS-ABp0dAQ |
link.rule.ids | 230,309,783,888,25578,76884 |
linkProvider | European Patent Office |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dT4MwEL8s0zjfdGo2P3kwvBGFAWMPxLACMh2wzLrsjbRdSfYyF4fx3_dANn3Rt6ZN7tpLrne_690V4FbPmSW4EGXkHgEKsxca6-eWpgvLltI2BmavLHCOEzt6NZ_m1rwBy20tTNUn9LNqjogaJVDfi-q-Xv8Esfwqt3Jzx5c49fYQUtdXa3SM5gttmuoP3WCS-ilRCXGJpyZTF5kiuOh5CJT20MN2yjb7wWxYFqWsf1uU8Aj2J0hsVRxDQ67a0CLbj9facBDX7904rFVvcwKdOKBR6r8oCNsUOg08OkoelYjMTkEJA0oiDVlku-NkxNttpncGTUT5sgMKGziGnqP3JIVp5lxnhjCk5LluG33nnrMudP8kc_7P2g20IhqPs_Eoeb6Aw1JG3ylsl9As3j_kFdrUgl9X0vgCskV29A |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=METHODS+FOR+TREATING+HCV&rft.inventor=BERNSTEIN%2C+BARRY+M&rft.inventor=LIN%2C+CHIH-WEI&rft.inventor=CAMPBELL%2C+ANDREW+L&rft.inventor=LIU%2C+WEI&rft.inventor=AWNI%2C+WALID+M&rft.inventor=MENON%2C+RAJEEV+M&rft.inventor=PODSADECKI%2C+THOMAS+J&rft.inventor=WANG%2C+TIANLI&rft.inventor=DUTTA%2C+SANDEEP&rft.date=2015-10-08&rft.externalDBID=A1&rft.externalDocID=CA2942823A1 |